Literature DB >> 1861222

Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis.

M P Sheehan1, D J Atherton, V Broadbent, J Pritchard.   

Abstract

In 16 children with multisystem Langerhans cell histiocytosis (mean age 22 months, range 5 to 36 months) severe symptomatic skin involvement was treated with topical nitrogen mustard (mechlorethamine hydrochloride). In each case, rapid clinical improvement occurred within 10 days; subsequent complete healing was observed in 14 children, and partial healing in 2 others in whom treatment was a component of palliative care. Mean duration of treatment was 3.5 months (range 2 to 6 months). Systemic treatment was averted in 11 patients because response to topical therapy was so favorable, but bone marrow or respiratory failure led to a fatal outcome in 5 other patients. Adverse effects were minimal. One patient developed contact allergy to topical nitrogen mustard after 2 years of intermittent therapy, but was successfully desensitized and was then able to continue treatment. We conclude that the topical application of nitrogen mustard is an effective treatment for cutaneous Langerhans cell histiocytosis. Although adverse effects were minimal in the short term, there remains concern about the possibility of long-term cutaneous carcinogenicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861222     DOI: 10.1016/s0022-3476(05)80752-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis.

Authors:  P H Hoeger; V R Nanduri; J I Harper; D A Atherton; J Pritchard
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

2.  Langerhans cell histiocytosis--clinical and epidemiological aspects.

Authors:  V Broadbent; R M Egeler; M E Nesbit
Journal:  Br J Cancer Suppl       Date:  1994-09

Review 3.  Treatment of Langerhans cell histiocytosis--evolution and current approaches.

Authors:  S Ladisch; H Gadner
Journal:  Br J Cancer Suppl       Date:  1994-09

4.  Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis.

Authors:  Jasmine H Francis; Y Pierre Gobin; Ruham Alshiekh Nasany; Jared Knopman; Gary A Ulaner; Katherine S Panageas; Vaios Hatzoglou; Kim Salvaggio; David H Abramson; Athos Patsalides; Eli L Diamond
Journal:  Neurology       Date:  2021-05-12       Impact factor: 9.910

5.  Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis.

Authors:  Valérie Failla; Odile Wauters; Marie Caucanas; Nazli Nikkels-Tassoudji; Arjen F Nikkels
Journal:  Rare Tumors       Date:  2010-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.